Contact us

TIRmed's Recent Dermal Study Yields Promising Results

In a recent development, TIRmed has conducted a biodistribution study that has yielded very promising results. The study, focused on...

Pirkko Tamsen joins the board of directors

Stockholm, 3 August 2023 - TIRmed Pharma is pleased to announce the appointment of Pirkko Tamsen as a new member of its Board of...

Welcome Jianjian and Amirreza - Market intelligence internship

We're excited to introduce our two new interns, Amirreza and Jianjian, who have been driving a market intelligence research project this...

Recruitment of dogs for proof of concept study completed

We are excited to announce that recruitment of 51 dogs with Atopic Dermatitis for the pivotal proof of concept study has been completed....

Utlysning - söker patienter med atopiskt eksem för intervju

Vi på TIRmed samarbetar tillsammans med Atopikerna för en patientundersökning. TIRmed Pharma håller just nu på att utveckla en ny kräm...

TIR-C selected for IVA's 100 list

TIRmed Pharma's project to developing TIR-C has been listed by Kungliga IngenjörsVetenskapsakademien (IVA) in their annual 100 list as...

TIRmed Pharma consortium receives grant of 1.5 MSEK from Vinnova

Vinnova, together with Swelife and Medtech4health, have jointly called for new innovative projects within life science and medical...

TIRmed Pharma initiates permeability study with leading CRO

TIRmed Pharma have begun a permeability study on their cream targeting Atopic Dermatitis, TIR-C. The study will showcase its ability to...

TIRmed Pharma raises 5.4 MSEK in equity for pre-clinical development

Eczema is a common disease affecting up to 20% of children and approximately 3% of adults, with a drugs market estimated up to 75 BSEK...

New publication

Amelioration of Compound 48/80-Mediated Itch and LL-37-Induced Inflammation by a Single-Stranded Oligonucleotide Authors: Aleksandra...

TIRmed Pharma AB

Alviksvägen 1, 167 53 Stockholm